Revenue ($USD) : $2,909,800,000
R&D spend : $484,200,000.00
Employees : 7,600
Fiscal year end : 12/31/22
CEO : Kevin Sayer

Dexcom, a developer of continuous glucose monitoring (CGM) technology, continued its rapid growth in 2023 with the launch of its next-generation G7.

Soon after, a new Medicare guideline implemented in April increased the addressable market for the company’s CGM.

The San Diego-based company is now shifting its focus toward using its technology beyond diabetes management, with eyes on bringing its sensors to even more users. –SW